KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Portfolio Pulse from Avi Kapoor
KB Home reported better-than-expected earnings and sales for its second quarter, leading to a 4.2% rise in its stock price. Other notable stock movements include Ocular Therapeutix, Applied Digital, Ranpak Holdings, ImmunityBio, Harrow, ZKH Group, NANO Nuclear Energy, Himax Technologies, Globant, Bilibili, Super Micro Computer, Accenture, ZIM Integrated Shipping, WestRock, Advanced Micro Devices, Kohl’s, and Gilead Sciences, all of which saw significant gains.
June 20, 2024 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Applied Digital Corporation jumped 15.3% to $5.95.
The significant price increase suggests positive market sentiment, likely driven by recent developments or news.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Gilead Sciences rose 4.1% to $65.76 after announcing results from an interim analysis of a Phase 3 trial, showing Lenacapavir demonstrated 100% efficacy for HIV prevention.
The positive Phase 3 trial results for Lenacapavir are likely to boost investor confidence and drive short-term gains for Gilead Sciences.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 85
POSITIVE IMPACT
Harrow shares jumped 12.2% to $19.81 after announcing the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL.
The progress in manufacturing TRIESENCE is a positive development, likely to drive short-term gains for Harrow.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 75
POSITIVE IMPACT
ImmunityBio gained 13.6% to $7.08 after announcing insurance coverage of ANKTIVA across multiple states with first commercial doses administered.
The announcement of insurance coverage and the administration of the first commercial doses are likely to boost investor confidence and drive short-term gains.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
KB Home reported quarterly earnings of $2.15 per share, beating the analyst consensus estimate of $1.78. Quarterly sales were $1.71 billion, surpassing the estimate of $1.651 billion. Shares rose 4.2% to $70.91.
The better-than-expected earnings and sales results are likely to positively impact KB Home's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Ocular Therapeutix shares climbed 16% to $6.36 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.
The upgrade from TD Cowen and the increased price target are likely to drive positive sentiment and short-term gains for Ocular Therapeutix.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80